【11月11日招银国际看好多只医药股并予“买入”评级】11月11日，招银国际发布研究报告，指出MSCI中国医疗指数年初至今累计升幅达59.5%，跑赢MSCI中国指数24%。近期医药板块回调，10月初起回落约10%，招银国际认为部分股份估值较低，仍具吸引力。该行看好三生制药、固生堂、巨子生物、药明合联、信达生物及中生制药，均给予“买入”评级。 招银国际预期，融资活动恢复，创新药出海交易规模扩张，国内...
Source Link【11月11日招银国际看好多只医药股并予“买入”评级】11月11日，招银国际发布研究报告，指出MSCI中国医疗指数年初至今累计升幅达59.5%，跑赢MSCI中国指数24%。近期医药板块回调，10月初起回落约10%，招银国际认为部分股份估值较低，仍具吸引力。该行看好三生制药、固生堂、巨子生物、药明合联、信达生物及中生制药，均给予“买入”评级。 招银国际预期，融资活动恢复，创新药出海交易规模扩张，国内...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.